Laura Pelletier

Univ Paris Est Creteil, INSERM U955
Creteil, 94010, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Follicular Helper T-Cell Lymphomas With Epstein-Barr Virus-Positive Neoplastic Cells: A Rare Scenario With Diagnostic Implications.

Follicular Helper T-Cell Lymphomas With Epstein-Barr Virus-Positive Neoplastic Cells: A Rare Scenario With Diagnostic Implications.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: June 04, 2025

Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas.

Targeting of CD28 and CD38 as a potential novel therapeutic strategy for peripheral T-cell lymphomas.

Journal: Scientific reports

Published: April 04, 2025

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Angioimmunoblastic T-cell lymphoma and Kaposi sarcoma: A fortuitous collision?

Journal: Histopathology

Published: August 26, 2023

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma.

Journal: Haematologica

Published: October 04, 2022

RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.

RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.

Journal: Journal of hepatology

Published: September 22, 2022

Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.

Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.

Journal: The British journal of dermatology

Published: April 25, 2022

PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

PD1 in Sézary syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 15, 2021

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma.

Journal: Blood advances

Published: July 29, 2020

Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α.

Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α.

Journal: Cancers

Published: July 10, 2020

Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.

Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders: A Clinical, Pathologic, and Molecular Study of 60 Cases Presenting With a Single Lesion: A Multicenter Study of the French Cutaneous Lymphoma Study Group.

Journal: The American journal of surgical pathology

Published: April 10, 2020

DNA methylation profiling of hepatosplenic T-cell lymphoma.

DNA methylation profiling of hepatosplenic T-cell lymphoma.

Journal: Haematologica

Published: October 20, 2018

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma.

Journal: Blood

Published: October 04, 2018

Showing 1-12 of 16

Last Updated: 09/26/2026